JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Benzinga · 1d ago
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.